Myricx Bio won the Series A Raise of the Year award at the Life Science eXecutives 2024 European Lifestars Awards
Myricx Bio were honoured to have been selected by the judges of the Informa Connect LSX - partnering for Life Science eXecutives 2024 European Lifestars Awards - Celebrating Life Science Leaders as the winner of the Series A Raise of the Year award.
Representing the Myricx team on the night of the event were Robin Carr, Francesca Zammarchi, Julie Mead and Robert McLeod (pictured).
Myricx Bio is a UK biotech company which grew from a spinout based on research carried out in the Tate group at Imperial and the Francis Crick Institute. Myricx Bio is focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival.
Congratulations to Myricx Bio on their continued success!
Article text (excluding photos or graphics) © Imperial College London.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
Reporter
Edward Bartlett
Department of Chemistry
